Clinical trials for Cancer in United States

A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

Study ID: NCT05829226

Sponsor

Pureech

Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study

Study ID: NCT06052826

Sponsor

City of Hope Medical Center

Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma

Study ID: NCT02203526

Sponsor

National Cancer Institute (NCI)

MDMA-assisted Therapy for Adjustment Disorder (AD) in Dyads of Patients With Cancer and a Concerned Significant Other

Study ID: NCT05584826

Sponsor

Sunstone Medical

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Study ID: NCT06377566

Sponsor

Memorial Sloan Kettering Cancer Center

Metabolomics and Genetic Diagnosing Pancreatic Neuroendocrine Tumors in MEN1 Patients

Study ID: NCT03048266

Sponsor

M.D. Anderson Cancer Center

Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer

Study ID: NCT05493566

Sponsor

Emory University

Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC

Study ID: NCT05814666

Sponsor

Flamingo Therapeutics NV

Tranexamic Acid in Reducing Blood Loss in Patients With Pelvic Tumors Undergoing Hemipelvectomy Surgery

Study ID: NCT03128866

Sponsor

M.D. Anderson Cancer Center

Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

Study ID: NCT02315326

Sponsor

Memorial Sloan Kettering Cancer Center